CX Partners-backed Veeda Lifesciences eyes majority stake sale at upto $400 million valuation ↗
Veeda Lifesciences has restarted a process to sell a majority stake at a $300-400 million valuation, with existing investor CX Partners expected to exit and fresh capital aimed at expansion.
Open on desktop to take part.
0 comments
Comments are posted by users and are not reviewed by Bazaar Updates.
Open on desktop to take part.
Sign in to comment.
No comments yet.